To read the full story, subscribe or sign in.

Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug

July 3, 2007

Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 9, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

ASH 2025: Tec-dara shines on ‘functional cure’ Majestec-3 MM data

BioWorld

Impressive results of a potential second-line combination treatment for multiple myeloma from the Majestec-3 trial of teclistamab plus daratumumab raised eyebrows...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...